CASSAVA SCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Principal Executive
Cassava Sciences, Inc.
(Registrant)
/s/ REMI BARBIER
Remi Barbier,
Chairman of the Board of Directors,
President and Chief Executive Officer
Dated: February 28, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ REMI BARBIER | President, Chief Executive Officer and | February 28, 2024 |
| Remi Barbier | Chairman of the Board of Directors | |
| (Principal Executive Officer) | ||
| /s/ ERIC J. SCHOEN | Chief Financial Officer | February 28, 2024 |
| Eric J. Schoen | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ ROBERT ANDERSON, JR. | Director | February 28, 2024 |
| Robert Anderson, Jr. | ||
| /s/ RICHARD J. BARRY | Director | February 28, 2024 |
| Richard J. Barry | ||
| /s/ PIERRE GRAVIER | Director | February 28, 2024 |
| Pierre Gravier | ||
| /s/ ROBERT Z. GUSSIN, PH.D. | Director | February 28, 2024 |
| Robert Z. Gussin, Ph.D. | ||
| /s/ CLAUDE NICAISE, M.D. | Director | February 28, 2024 |
| Claude Nicaise, M.D. | ||
| /s/ MICHAEL J. O'DONNELL, ESQ. | Director | February 28, 2024 |
| Michael J. O'Donnell, Esq. | ||
| /s/ SANFORD R. ROBERTSON | Director | February 28, 2024 |
| Sanford R. Robertson | ||
| /s/ PATRICK SCANNON, M.D., PH.D. | Director | February 28, 2024 |
| Patrick Scannon, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.